±³½Ç¼Ò°³

    • home
    • ±³½Ç¼Ò°³
    • ±âÃÊÀÇÇÐ

±âÃÊÀÇÇÐ

  • ÀüÀӺα³¼ö(ÀÇ°ú´ëÇÐ)
  • ÀÌ¿¬Á¾
  • Àü°øºÐ¾ß £ü
  • ¿¬¶ôó     £ü (ÀüÈ­) 031-299-6194 / (fax)
  • À̸ÞÀÏ     £ü ylee69@skku.edu

ÁÖ¿ä°æ·Â

  • 1997 ~ 2004 ¼­¿ï´ëÇб³ ¾àÇдëÇÐ (¾àÇаú, ÀÌÇлç)
    2004 ~ 2006 ¼­¿ï´ëÇб³ ¾àÇдëÇÐ (º´Å»ý¸®ÇÐ, ÀÌÇм®»ç) 2006 ~ 2011 Johns Hopkins University, SOM (Molecular & Cellular Physiology, ÀÌÇйڻç)
    2011 ~ 2015 Johns Hopkins University, SOM (Neurobiology, Postdoctoral fellow)
    2015 ~ ÇöÀç ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ (Molecular Cell Biology-Pharmacology, ºÎ±³¼ö)

ÁÖ¿ä°ü½É¿¬±¸

  • 1.ÆÄŲ½¼º´ À¯ÀüÀÚ ¼¼Æ÷ µ¿¹° ¸ðµ¨ ±¸Ãà: ÆÄŲ½¼ÁúȯÀº °¡Àå ¹ß»ýºóµµ°¡ ³ôÀº ³ëÀμº ½Å°æ ÅðÇ༺ ¿îµ¿Àå¾ÖÁúȯÀÔ´Ï´Ù. ÁúȯÀÇ ´ëÇ¥ º´¸®ÀÎ Á¡ÁøÀûÀÎ µµÆĹΠ½Å°æ¼¼Æ÷ÀÇ »ç¸ê ±âÀÛÀ» ÀÌÇØÇϱâ À§Çؼ­´Â ÆÄŲ½¼ Áúȯ °ü·Ã À¯ÀüÀÚµéÀ» ÀÌ¿ëÇÑ ¼¼Æ÷ ȤÀº µ¿¹° ¸ðµ¨ÀÇ ±¸ÃàÀÌ ±× ¿¬±¸ÀÇ ½ÃÀÛÀÌ µÇ°Ú½À´Ï´Ù. ÀúÈñ ½ÇÇè½Ç¿¡¼­´Â ÃÖ±äÀÇ Tet-Off ±â¼ú¹× CRISPR/cas9 ½Ã½ºÅÛÀ» ÀÌ¿ëÇÏ¿© ¼®¹Ú»ç ÇлýµéÀÌ Á÷Á¢ ¼¼Æ÷ÁÖ¸¦ ±¸ÃàÇÏ°í ¿¬±¸¿¡ È°¿ëÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» ±â¸¦¼ö Àִ ȯ°æÀ» Á¦°øÇÒ °ÍÀÔ´Ï´Ù.


    2.ÆÄŲ½¼º´ À¯¹ß ¼¼Æ÷ »ç¸ê ºÐÀÚ ±âÀÛ ¿¬±¸: ½Å°æ ¼¼Æ÷ »ç¸ê ±âÀÛÀ¸·Î ÃÖ±Ù È°¹ßÈ÷ ¿¬±¸µÇ°í ÀÖ´Â poly (ADP-ribose) polymerase (PARP1)ÀÇ °úÈ°¼ºÈ­¿¡ ÀÇÇØ À¯¹ßµÇ´Â Parthanatos°¡ ÀÖ½À´Ï´Ù. ÆÄŲ½¼ Áúȯ¿¡¼­ÀÇ º´¸®¿¡ ¿¬°ü¼ºÀ» °¡Áø °ÍÀ¸·Î ÀúÈñ ¿¬±¸´ÜÀÌ Ã³À½ ¹àÇô³Â°í, ´Ù¸¥ ¾ËÃ÷ÇÏÀÌ¸Ó º´À» Æ÷ÇÔÇÑ ½Å°æ ÅðÇ༺ Áúȯ¿¡¼­ÀÇ parthanatosÀÇ ¿ªÇÒ ±×¸®°í ¼¼Æ÷ÁÖ ¸ðµ¨À» ÀÌ¿ëÇØ ¹àÈ÷°Ô µÉ ¿©·¯ ½Å°æº´¸® °ü¿© ÀÎÀÚµéÀÇ »óÈ£ ÀÛ¿ëÀ» ¿¬±¸ÇÒ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ¸¶·ÃÇÏ°í ¾à¹° Ä¡·áÀÇ Å¸°ÙÀ» ¹ß±¼ÇÏ´Â °ÍÀÌ ÀúÈñ ½ÇÇè½ÇÀÇ ¿¬±¸ ¸ñÇ¥ÀÔ´Ï´Ù.


    3. ÆÄŲ½¼º´ Ä¡·áÁ¦ °³¹ß ¹× Á¶±âÁø´Ü ¸¶Ä¿ ¹ß±¼: À§ÀÇ ¼¼Æ÷ÁÖ ¸ðµ¨ ±×¸®°í ½Å°æ¼¼Æ÷»ç¸ê±âÀÛ°úÀÇ ¿¬°è¼ºÀ» ÅëÇÑ ¿¬±¸´Â Ä¡·á Ÿ°Ù ¹ß±¼ »Ó¸¸ ¾Æ´Ï¶ó, Ä¡·á ¼±µµ ¹°Áú °³¹ß¿¡ À־ ÀÌ¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ¸®Æ÷ÅÍ ¿¡¼¼ÀÌ, highthroughput ½ºÅ©¸®´× ½Ã½ºÅÛÀ» ÀÌ¿ëÇÏ¿© Áúȯ Ä¡·á¿¡ ÀÀ¿ë °¡´ÉÇÑ È­ÇÕ¹°À» ¹ß±¼ÇÏ°í À̸¦ Á÷Á¢ in vivo Áúȯ µ¿¹° ¸ðµ¨¿¡ Ä¡·á È¿°ú¸¦ È®ÀÎÇÔÀ¸·Î½á ³ëÀμº ÁúȯÀÌ »õ·Î¿î »çȸ ¹®Á¦·Î ´ëµÎµÇ´Â ½ÃÁ¡¿¡¼­ ±×¸®°í Ä¡·áÁ¦°¡ Àü¹«ÇÏ ÆÄŲ½¼ Áúȯ ºÐ¾ß¿¡¼­ ÇØ°áÁ¡À» ã¾Æº¸°íÀÚ ÇÕ´Ï´Ù.

´ëÇ¥¿¬±¸¾÷Àû

  • 1. Kim H et al. Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson''s disease. Sci Rep. 2019 Jul 319(1) (±³½Å)

    2. Ham S et al. Cell-Based Screen Using Amyloid Mimic ¥â23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of ¥á-Synuclein and Huntingtin Aggregates. Mol Cells. 2019 Jun 3042(6):480-494 (±³½Å)

    3. Kim H et al. Rhododendrin-Induced RNF146 Expression via Estrogen Receptor ¥â Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress. Int J Mol Sci. 2019 Apr 1020(7). (±³½Å)

    4. Yun SP et al. ¥á-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener. 2018 Jan 813(1) (±³½Å)

    5. Kim H et al. Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson''s disease models. Oncotarget. 2017 Oct 118(63) (±³½Å)

    6. Kang H et al. PARIS reprograms glucose metabolism by HIF-1¥á induction in dopaminergic neurodegeneration..Biochem Biophys Res Commun. 2018 Jan 22495(4) (±³½Å)

    7. Kim H et al. CRISPR-Cas9 Mediated Telomere Removal Leads to Mitochondrial Stress and Protein Aggregation. Int J Mol Sci. 2017 Oct 318(10) (±³½Å)

    8. Kang H et al. Activation of the ATF2/CREB-PGC-1¥á pathway by metformin leads to dopaminergic neuroprotection. Oncotarget. 2017 Jul 258(30):48603-48618.(±³½Å)

    9. Yun SP et al. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Cell Death Dis. 2017 Apr 68(4) (±³½Å)

    10. Ham S et al. Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson''s disease model. Sci Rep. 2017 Apr 37(1) (±³½Å)

    11. Lee Y et al. PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Rep. 2017 Jan 2418(4):918-932 (1ÀúÀÚ)